Hims pivots to branded Tirzepatide, generic Liraglutide
Hims changes to selling branded Tirzepatide along with the Liraglutide generic on their telehealth platform, after the shortage ends.
Latest
STRIDE study: GLP1s vs peripheral artery disease (PAD)
Walk farther with GLP1s -- results from the STRIDE study show Semaglutide effective for treating Peripheral Artery Disease (PAD)
Novo Nordisk licenses GLP1 drug from United BioTechnology, a Chinese research firm
Novo Nordisk licenses the right to sell a new GLP1 being developed in China -- 15% weight loss in 12 weeks (in an admittedly small study).
Novo Nordisk offers cheaper Wegovy
Novo Nordisk makes available cheaper Wegovy, via it's savings plan, purchasable at local pharmacies.
VK2735's manufacturing alliance with CordenPharma
Viking secures a manufacturing alliance with CordenPharma, promising "metric tons" of production of VK2735
BRP - a new GLP1-like peptide
We dive into BRP, a possible new future for GLP1-like formulation that could be even more beneficial without the downsides.
HIMS ends compounded Semaglutide offering
Hims announces it will stop providing compounded Semaglutide, after removal from the FDA shortage list.
Semaglutide removed from shortage list
It happened sooner than we expected -- the FDA has announced Semaglutide shortage resolution, removing it from the shortage list.
Mexico and GLP1s
We explore GLP1 medical tourism, supply issues, and adoption of generic GLP1 Receptor Agonists in Mexico.
Shortages threaten corporate profits, likely to end soon
We think the GLP1 shortage is going to end in the first half of 2025. Here's why.
Ozempic approved for Chronic Kidney Disease
The FDA has approved Semaglutide for chronic kidney disease. We explore research and the possible implications for insurance coverage and more.
Tradjenta: An alternative to GLP1 for Type 2 Diabetes
We take a look at one of the alternatives to GLP1s that has been on the market a long time -- Tradjenta.
category:watercooler
GLP1 use by younger people
We dig into the reports of younger people using GLP1s like Ozempic, Wegovy and others.
company:novo-nordisk
Novo's Amycretin delivers great Phase 2 results
Novo Nordisk's Amycretin produces stellar results in Phase 2 trials -- we dive into Amycretin and other new drugs to see how it compares.
category:news
The battle for compounded GLP1 continues
The battle for compounded GLP1s rages on -- powerful organizations with profit incentives continue to push for compounded GLP1s, with consumers caught in the middle.
government
Government Price negotiations on Ozempic and Wegovy
The government has selected Ozempic and Wegovy for price negotiations -- are we going to see cheaper prices?
category:side-effects
Pancreatitis and Gallstones after massive weight loss
We look into pancreatitis and gallstones issues that caused one death and more hospitalizations, caused at least in part by GLP1s
category:howto
What's the best injection site for GLP1s?
What's the best site for injecting Ozempic, Wegovy, Mounjaro, or Zepbound? We check anecdata, manufacturers, and 3rd parties.
category:benefits
Zepbound coverage for Sleep Apnea gets Agency approval
Center for Medicare and Medicaid declared that Zepbound is covered by insurance for treating Sleep Apnea, given it's effectiveness.
category:news
Robert F. Kennedy Jr vs GLP1
RFK Jr.'s appointment and it's effect on GLP1s. Is it truly anti-GLP1? Or a case of tactics?
research
Research suggesting GLP1 is a brain drug
Why has modern scientific opinion shifted to GLP1 being a brain drug rather than a gut drug? We dive into the critical research paper supporting the shift.
usecase:kidney-disease
Tirzepatide's benefits extend to Kidney Disease
Tirzepatide (Mounjaro, Zepbound) shows results in weight loss and Hba1c reduction for southerners, critical to kidney disease treatment.
company:hikma
Another Generic Liraglutide launch: Hikma Phamaceuticals
A new player enters the generic GLP1 market - Hikma Pharmaceuticals. As the second generic Liraglutide provider, accessibility of GLP1s has never been better.
category:news
HIMS to offer Liraglutide after shortage rule changes
HIMS leans into Liraglutide as a replacement for Semaglutide in the face of shortage rule changes. Is it good enough?